Sensational news heaved Surface Oncology (SURF) shares higher in the Postmarket hours

Today, Surface Oncology (Nasdaq: SURF) surged 10.46% to 9.4 in the after-hours as it officially announced an agreement with GSK to develop and commercialize Surface Oncology’sOncology’s preclinical program, SRF813, an antibody that aims to inhibit PVRIG, an inhibitory protein expressed on natural killer cells (NK cells) and T cells.

As part of the agreement, GSK will pay an upfront payment of $85 million. Surface Oncology can expect to receive up to an additional $730 million in further milestone payments, as well as receive tiered royalties on global net sales.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Read More

“We are extremely pleased to be entering into this agreement with GSK given the strong strategic fit for SRF813 within GSK’sGSK’s oncology portfolio, including the possibility of pursuing compelling novel clinical combinations. We believe that the economics of the transaction support our efforts further to advance our wholly-owned clinical programs, SRF617 and SRF388, while also progressing SRF114, our CCR8 targeted program,” said Jeff Goater, CEO at Surface Oncology.

SRF813, which is a natural killer cell approach, complements our existing programs focusing on T-cell/adaptive immunity,” said Dr. Axel Hoos, GSK’sGSK’s senior vice president and head of oncology R&D.

After the GSK license agreement, Surface Oncology expects its current cash and cash equivalents,

to be sufficient for the company company’s operations through the year 2023.

Most Popular

Related posts